Competing interests
Diabetes
DIABETES
EF has acted as an advisor to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Polfa Tarchomin, and reports honoraria for speaking from AstraZeneca, Bioton, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Polfa Tarchomin, Sanofi, and Servier. PP discloses no conflicts of interest. JB declares research grants from Eli Lilly and Company, ReCor, and Ablative Solutions; and consultant fees from Medtronic and Up-to-Date. CN, SR, AH, NNA, MK, and HK are employees and shareholders of Eli Lilly and Company. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly and Company, AstraZeneca, Merck, Novo Nordisk, and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, DKSH, Zuellig, Sanofi, Jiangsu Hanson, and Carbon Brand; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi, Kowa, Pfizer, Hanmi and Viatris.